MAY 24, 2019 2:36 PM PDT

New Therapeutic Target for Depression

WRITTEN BY: Nouran Amin

In a study published in the Journal of Psychopharmacology, a new drug target for the treatment of depression has been identified by researchers at the Department of Human Physiology of the UMA Faculty of Medicine.

The study stemmed from the research group, “Neurochemistry of the Transmission in the Central Nervous System”, co-directed by Professor Zaida Díaz-Cabiale, where they identified ‘GAL (1-15)’--part of the neuropeptide molecule called Galanin.

Galanin is central to the common symptom of depression—anhedonia, the loss of pleasure in daily activities.

“We have verified through different experiments how animals modify their response to high-reinforcement appetitive stimuli, such as saccharine or sexual attraction, after the administration of the Galanin fragment”, explains researcher Carmelo Millón, one of the authors of this study. “The understanding of these mechanisms opens the way for endless therapeutic strategies, hence its importance.”

Researchers from Karolinska Institute in Sweden also collaborated on the study and examined the molecular interactions of brain reinforcement system. They observed that the brains' ability to support positive behavior was inhibited by the Galanin fragment which reaffirmed the initial findings.

Most therapeutics for depression are SSRIs (selective serotonin reuptake inhibitors)—such drugs can take up to two weeks to start showing signs of treatment with a further 30 percent of patients who receive the medication are resistant to the treatment.

Learn more about the future of depression treatments:

Source: Drug Target Review

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
NOV 20, 2020
Drug Discovery & Development
Hyperbaric Oxygen Treatments Reverse Aging
NOV 20, 2020
Hyperbaric Oxygen Treatments Reverse Aging
Researchers from Israel have found that hyperbaric oxygen treatments (HBOT) in healthy aging adults can prevent blood ce ...
NOV 22, 2020
Cannabis Sciences
Public Believes CBD is Cure-All Despite Lack of Evidence
NOV 22, 2020
Public Believes CBD is Cure-All Despite Lack of Evidence
Many people think that cannabidiol (CBD), a non-psychoactive compound in cannabis, can reduce symptoms from various cond ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
DEC 01, 2020
Drug Discovery & Development
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
DEC 01, 2020
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
Researchers from the Universities of Oxford and Birmingham in the UK have found that otilimab can reduce infla ...
Loading Comments...